Precision BioSciences, Inc.
DTILAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 9, 2026 | Oppenheimer | $20.00(+195%) | $6.77 | TheFly | |
| Mar 13, 2026 | Jefferies | Maury Raycroft | $19.00(+235%) | $5.67 | StreetInsider |
| Apr 1, 2024 | BTIG | Justin Zelin | $30.00(+121%) | $13.56 | TheFly |
| Nov 10, 2022 | Goldman Sachs | $1.00(-28%) | $1.38 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 10, 2025 |
| BMO Capital | upgrade | Market Perform →Outperform | Jan 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 18, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 27, 2023 |
| BTIG | maintain | Buy | Jul 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 31, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 15, 2023 |
| BMO Capital | downgrade | Outperform →Market Perform | Mar 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 9, 2022 |
| Goldman Sachs | maintain | Neutral | Nov 9, 2022 |
| Goldman Sachs | maintain | Neutral | Aug 8, 2022 |
| BMO Capital | maintain | Outperform | Jun 17, 2022 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.99| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.28 | $-0.85 | $1.3M | $1.4M |
| Aug 6, 2026 | $-1.26 | $-0.80 | — | $740.0K |
| May 5, 2026 | $-0.75 | $-0.27 | $10.8M | $4.0M |
| Mar 12, 2026 | $1.05 | $-0.21 | $34.2M | $9.1M |
| Nov 3, 2025 | $-1.84 | $-0.31 | $13.0K | $9.1M |
| Aug 7, 2025 | $-2.13 | $-0.09 | $18.0K | $5.4M |
| May 15, 2025 | $-2.21 | $-0.43 | $29.0K | $6.3M |
| Mar 26, 2025 | $-3.20 | $-2.09 | $638.0K | $10.0M |
News
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the pricing of an underwritten offering of 10,235,077 shares of its common stock at a price of $7.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 5,893,964 shares of its common stock.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced new and updated Phase 1 clinical data from the ongoing ELIMINATE-B study of PBGENE-HBV to be presented in a late-breaking oral presentation on Sunday, November 8 at 2:15pm MST, at the American Association for the Study of Liver Diseases (AASLD) The L.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the first patient treated with PBGENE-DMD in the Phase 1/2 FUNCTION-DMD clinical trial for Duchenne muscular dystrophy (DMD). No serious adverse eve.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update. “We entered 2026 with a clear plan to deliver multiple important clinical and operational milestones this year and we have made significant progress exec.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2026 and provide a business update on Tuesday, November 3, 2026.About Precision BioSciences, Inc.Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving l…
Precision BioSciences, Inc. (NASDAQ: DTIL - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $6.44 and traded as low as $6.37. Precision BioSciences shares last traded at $6.41, with a volume of 266,678 shares. Analyst Ratings Changes
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The Liver Meeting 2026, the 77th annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting 2026 will take place November 5-9 in Denv.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durab.
PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral reservoir in patients. Durable off-treatment viral control remains unproven, making the next ELIMINATE-B updates decisive for the investment thesis. PBGENE-DMD offers a second validation path. However, their program still lacks disclosed human safety or efficacy data.